Format

Send to

Choose Destination
Allergy. 2017 Dec;72(12):1953-1961. doi: 10.1111/all.13202. Epub 2017 Jun 14.

Lung function parameters in omalizumab responder patients: An interesting tool?

Author information

1
INSERM U 600, UMR 6212, Université de la Méditerranée., Marseille, France.
2
Université de la Réunion, St Denis, France.
3
Service de Pneumologie, CHIC de Créteil, Créteil, France.
4
Service de Pneumologie, CHU de Nimes, Tarbes, France.
5
Service de Pneumologie, CHG de Bigorre, Tarbes, France.
6
Cabinet de Pneumologie, Bastia, France.
7
Service de Pneumologie, CHU de Tours, Tours, France.
8
Cabinet de Pneumologie, Bordeaux, France.
9
Service de Pneumologie, Polyclinique des Fleurs, Ollioules, France.
10
Service de Pneumologie, CHU de Limoges, Limoges, France.
11
Service de Pneumologie, Centre médical Toki Eder, Cambo les Bains, France.
12
Service de Pneumologie, Clinique Pasteur, Toulouse, France.
13
Service de Pneumologie et d'allergologie, CH de la côte Basque, Bayonne, France.
14
Centre de Recherche Cardio-thoracique de Bordeaux, Univ. Bordeaux, U1045, CIC1401, Bordeaux, France.
15
Centre de Recherche Cardio-thoracique de Bordeaux, INSERM, U1045, CIC1401, Bordeaux, France.
16
Service d'Exploration Fonctionnelle Respiratoire, CHU de Bordeaux, CIC1401, Pessac, France.
17
Service de Pneumologie, CHU Reunion/GHSR, Saint-Pierre, France.
18
INSERM, UMR 1188 Diabète Athérothrombose Thérapies Réunion Océan Indien (DéTROI), Sainte-Clotilde, France.

Abstract

BACKGROUND:

Omalizumab, an anti-IgE antibody, is used to treat patients with severe allergic asthma. The evolution of lung function parameters over time and the difference between omalizumab responder and nonresponder patients remain inconclusive. The objective of this real-life study was to compare the changes in forced expiratory volume in 1 second (FEV1) of omalizumab responders and nonresponders at 6 months.

METHODS:

A multicenter analysis was performed in 10 secondary and tertiary institutions. Lung function parameters (forced vital capacity (FVC), pre- and postbronchodilator FEV1, residual volume (RV), and total lung capacity (TLC) were determined at baseline and at 6 months. Omalizumab response was assessed at the 6-month visit. In the omalizumab responder patients, lung function parameters were also obtained at 12, 18, and 24 months.

RESULTS:

Mean prebronchodilator FEV1 showed improvement in responders at 6 months, while a decrease was observed in nonresponders (+0.2±0.4 L and -0.1±0.4 L, respectively, P<.01). After an improvement at 6 months, pre- and postbronchodilator FEV1 remained stable at 12, 18, and 24 months. The FEV1/FVC remained unchanged over time, but the proportion of patients with an FEV1/FVC ratio <0.7 decreased at 6, 12, 18, and 24 months (55.2%, 54.0%, 54.0%, and 44.8%, respectively, P<.05). Mean RV values decreased at 6 months but increased at 12 months and 24 months (P<.05). Residual volume/total lung capacity (RV/TLC) ratio decreased at 6 months and remained unchanged at 24 months.

CONCLUSION:

After omalizumab initiation, FEV1 improved at 6 months in responder patients and then remained stable for 2 years. RV and RV/TLC improved at 6 months.

KEYWORDS:

FEV1; asthma; lung function; omalizumab

PMID:
28517027
DOI:
10.1111/all.13202
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center